In Europe, the legislation for marketing of medicinal products (MP) and IVDs
including predictive biomarker - based assays (Companion Diagnostics, CDx) are not directly linked which is challenging for co-development.
Not exact matches
His research interests
include new therapies,
predictive biomarkers, cancer survivorship, and quality of care.
Major focus areas
include human genome interpretation and genetic dissection of novel rare diseases,
predictive genomic signatures of response to therapy — especially cancer therapy, and novel sequencing - based assays as
biomarkers of disease.
Other areas of research
include designing novel therapies based on molecular pathways and identifying
predictive biomarkers in patients to design personalized, targeted therapies.
Our approach to achieving this goal focuses on three objectives: (1) to develop a reliable,
predictive panel of
biomarkers (
including both biological and bio-behavioral measures) that can identify children, youth, and parents showing evidence of toxic stress, and that can be collected in pediatric primary care settings; (2) to conduct basic, animal and human research on critical periods in development and individual differences in stress susceptibility, thereby informing the timing and design of a suite of new interventions that address the roots of stress - related diseases early in the life cycle; and (3) to build a strong, community - based infrastructure through which scientists, practitioners, parents, and community leaders can apply new scientific insights and innovative measures to the development of more effective interventions in the first three postnatal years.